LLM 2021 | Key myeloma discussion topics at LLM 2021
Ruben Niesvizky, MD, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, gives an overview of key discussion topics on multiple myeloma from the LLM meeting. During the meeting, it was agreed that measurable residual disease (MRD) is a very important tool to predict survival in both fit and frail patients with multiple myeloma. In addition, achieving MRD negativity in high-risk disease is indicative of improved outcomes. Prof. Niesvizky also talks on the relevance of consolidation therapy and argues that stem cell transplantation is still an important treatment strategy in this setting. However, it is still useful to try to achieve MRD negativity in the absence of transplantation. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.
